AVITA Medical to Participate in Upcoming Investor Conferences
07 September 2023 - 8:45AM
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative
medicine company leading the development and commercialization of
first-in-class devices and autologous cellular therapies for skin
restoration, today announced that its management team will
participate in the following upcoming investor conferences:
Morgan Stanley 21st Annual Global Healthcare Conference,
New York, NYWednesday, September 13, 2023, including a
fireside chat at 2:15 p.m. Eastern Time
Lake Street Capital Markets 7th Annual Best Ideas Growth
Conference, New York, NYThursday, September 14, 2023
Management will be participating in one-on-one and small group
meetings at these events. Those interested in attending should
reach out to their respective representatives. The live audio
webcast and archived recording of the fireside chat at the Morgan
Stanley conference will be available on the "Events &
Presentations" section of the Company's website at
https://ir.avitamedical.com.
About AVITA Medical, Inc.AVITA Medical® is a
regenerative medicine company leading the development and
commercialization of devices and autologous cellular therapies for
skin restoration. The RECELL® System technology platform, approved
by the Food and Drug Administration for the treatment of thermal
burn wounds and full-thickness skin defects and for repigmentation
of stable depigmented vitiligo lesions, harnesses the regenerative
properties of a patient’s own skin to create Spray-On Skin™ cells.
Delivered at the point-of-care, RECELL enables improved clinical
outcomes. RECELL is the catalyst of a new treatment paradigm and
AVITA Medical is leveraging its proven and differentiated
capabilities to develop first-in-class cellular therapies for
multiple indications.
In international markets, our products are approved under the
RECELL System brand to promote skin healing in a wide range of
applications including burns, soft tissue repair, vitiligo, and
aesthetics. The RECELL System is TGA-registered in Australia,
received CE-mark approval in Europe and has PMDA approval in
Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:Jessica
EkebergPhone +1-661-904-9269
investor@avitamedical.commedia@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA
Medical, Inc.
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From May 2023 to May 2024